Drug Type Antibody, Fusion protein |
Synonyms SGN17/19 |
Target |
Action stimulants |
Mechanism β-lactamase stimulants(Beta Lactamase stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Preclinical | United States | - | |
| Melanoma | Preclinical | United States | - |






